Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure Chaggar PS; Malkin CJ; Shaw SM; Williams SG; Channer KSCardiovasc Ther 2009[Fal]; 27 (3): 187-93Chronic heart failure (CHF) involves derangements in multiple neurohormonal axes leading to a procatabolic state and wasting syndrome associated with significant mortality. Catabolic abnormalities include excess catecholamines and glucocorticoids. Anabolic defects include deficiencies of sex steroids, insulin resistance, and growth hormone (GH) resistance. These abnormalities are also correlated with increased morbidity and mortality in CHF. Anabolic axes have been augmented in pilot studies in CHF with testosterone, GH, insulin-like growth factor-1, and GH secretagogues. Results have been varied although some treatments have been associated with improved surrogate endpoints. This review article explores the current understanding of metabolic derangements in CHF and highlights potential neuroendocrine treatment strategies.|Anabolic Agents/metabolism[MESH]|Animals[MESH]|Catecholamines/metabolism[MESH]|Glucocorticoids/metabolism[MESH]|Heart Failure/*drug therapy/metabolism[MESH]|Heart/*drug effects[MESH]|Human Growth Hormone/physiology[MESH]|Humans[MESH]|Insulin Resistance[MESH]|Neurosecretory Systems/*drug effects/metabolism[MESH]|Steroids/metabolism[MESH] |
